Projects
BMBF
Short description
Funding by the Federal Ministry of Education and Research (BMBF) within the framework of the “Integrated Genome Research Network” NGFNplus Program.
Collaborative Project
Deciphering oncogene dependencies in human cancer oncogene mutation space (Coordinator: Roman Thomas).
Subproject 3
Mutational analysis and its clinical implications in patients with lung cancer (Jürgen Wolf).
Subproject 4
Systematic High-Throughput-Analysis of mutations in the development of tumors (Roman Thomas).
EU 7th Framework Program
Short description
Funding from the European Community (7th Framework) within the framework of the “Curelung Lung Cancer Research” project
Project title
“Determining (epi)genetic therapeutic signatures for improving lung cancer prognosis”
NRW PerMed Program
Short description
Ministerium für Innovation, Wissenschaft und Forschung des Landes Nordrhein-Westfalen
Förderung durch das NRW-EU Ziel 2-Programm im Rahmen des “Europäischen Fonds für regionale Entwicklung” (EFRE).
Verbundprojekt
Entwicklung von ZweitgenerationsTyrosinkinasehemmern und Diagnostik für die personalisierte Therapie von Patienten mit EGFR- und FGFR-abhängigen Tumoren (Koordinator Roman Thomas)
Partner
Universität Köln (Roman Thomas, Reinhard Büttner, Jürgen Wolf), Lead Discovery Center GmbH Dortmund, Technische Universität Dortmund
Bayer Healthcare
Short description
Cooperation agreement to carry out an investigator-initiated phase I study (sponsored by LCGC ) to determine the “Recommended Phase 2 Dose” RP2D of sorafenib and everolimus with subsequent examination of the efficacy of the combination in KRAS mutant NSCLC patients (SORAVE-Study).
Boehringer Ingelheim
Short description
Cooperation agreement to carry out an investigator-initiated phase I study (sponsored by LCGC) to determine the “Recommended Phase 2 Dose” RP2D of BIBF 1120 and everolimus in patients with solid tumors.
Novartis
Short description
Collaboration to establish an investigator-initiated phase II study (sponsored by LCGC) to evaluate the efficacy and safety of the combination of trastuzumab and AUY922 in the treatment of advanced non-small cell lung cancer with HER2 overexpression or amplification or mutation (TRY-Study).
Pfizer
Short description
Cooperation Agreement to carry out an investigator-initiated, multicenter phase II study (sponsored by LCGC) to determine the efficacy of the ALK/ROS1 inhibitor crizotinib in NSCLC patients harbouring a ROS1 translocation in their tumor after firstline therapy (EUCROSS ) in collaboration with the Spanish Lung Cancer Group.
Roche
Short description
Cooperation agreement to carry out an investigator-initiated phase II study (sponsored by LCGC) for the evaluation of the early prediction of non-progression of non-small cell lung cancer during treatment with erlotinib and bevacizumab with fluorodeoxyglucose – F18 , F18- fluorothymidine and DCE – MRI.
Cooperation to carry out an investigator-initiated phase II study (sponsored by LCGC) to evaluate the efficacy and safety of the combination of trastuzumab and AUY922 in the treatment of advanced non-small cell lung cancer with HER2 overexpression or amplification or mutation.
SFB 832
Short description
The Special Research Center (SFB) 832 “Molecular basis and modulation of cellular interactions in the tumor microenvironment ” is an interdisciplinary research network in the Cologne – Bonn area, funded by the German Research Foundation (DFG).
The project A 6 is realized in collaboration with the LCGC.
Project title
Combined use of chemical-genetic and imaging techniques to validate anti-angiogenic properties of anti-angiogenic compounds.
Persons in charge
Roman Thomas, Roland Ulrich und Jürgen Wolf
Last Update: